Paolo Tarantino: Terrific ending for ESMO24 day one

Paolo Tarantino shared a post on X:

“Terrific ending for ESMO24 day one, getting to connect, chat, hug, celebrate with some of the kindest and strongest voices in oncology— thank you OncoDaily for one more superb party!”

Source: Paolo Tarantino/X

More posts featuring ESMO24 on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.